Navigation Links
Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
Date:7/6/2012

lly from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended March 31, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:

 James E. Fickenscher /
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Auxilium Announces Appointments to Enhance Leadership Team
3. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
4. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
7. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
8. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
9. UAS Laboratories Presents about Probiotic Selection Criteria, at Scientific Conference
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Southern Illinois University Edwardsville ... of vice president of instruction at Chippewa Valley Technical College (CVTC) and will ... opportunity to lead SIUE during the past three years,” Furst-Bowe said. “I want ...
(Date:6/29/2015)... ... June 29, 2015 , ... MediVet Biologics today announced ... agreement, MediVet will acquire the rights to a portfolio of cultures, products and ... development as a potential next-generation treatment for various musculoskeletal and internal medicine conditions ...
(Date:6/29/2015)... Md. , June 29, 2015  Neuralstem, Inc. ... cell technology to develop small molecule and cell therapy ... it has been approved for listing on the NASDAQ ... stock will continue to trade on the NYSE MKT ... on the NASDAQ Capital Market is expected to commence ...
(Date:6/29/2015)... -- Elsevier , a world-leading provider ... today announced the highlights of its journal Impact Factor ... Reports® (JCR) published by Thomson Reuters, Elsevier saw 55% ... 2014, ahead of the aggregate across other journals. In ... subject categories, up from 61 in 2013. ...
Breaking Biology Technology:SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... tracking the number and dimension of particles or droplets as they ... are specific and possibly unique, changes that are of critical importance ... provide you with the knowledge, information and best practices you need ... ...
... of a new system to study crystallization processes for ... name,Crystalline. , The Crystalline has ... to learn as much as possible about a drug ... "Avantium is proud to launch its next system ...
... Institute have discovered a new method for controlling ... potentially one step closer to realizing the mass ... sheet of carbon, was discovered in 2004 and ... silicon as the fundamental building blocks of nanoelectronics. ...
Cached Biology Technology:Maximize Data Analysis with METTLER TOLEDO FBRM 2Avantium Launches the Crystalline, a New Parallel System for Crystallization Research 2Light-speed nanotech: Controlling the nature of graphene 2
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... vast majority of patients who had a successful ... need mitral valve surgery three years after their ... of the left ventricle (commonly known as reverse ... the Cardiovascular Research Foundations (CRF) nineteenth annual Transcatheter ...
... D.C. October 24, 2007 - The U.S. Senate ... Appropriations Bill (S.1710), including a provision that directs the ... Access Policy by requiring rather than requesting participation by ... House Appropriations Bill, which contains a similar provision, in ...
... Germany-October 24, 2007-Harvard University,s Office of Technology Development ... jointly establish the BASF Advanced Research Initiative. ... and Applied Sciences (SEAS) the initiative will benefit ... throughout the University. Set up as a ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Mandate for public access to NIH-funded research poised to become law 2BASF and Harvard University announce extensive research collaboration 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: